Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $43.33

NewAmsterdam Pharma (NASDAQ:NAMS) has been assigned an average rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $43.33.

A number of equities analysts have recently issued reports on the stock. Scotiabank increased their price objective on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 27th. Needham & Company LLC dropped their price objective on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. UBS Group set a $41.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Friday, January 24th.

Insider Buying and Selling

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 100,728 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $26.10, for a total value of $2,629,000.80. Following the completion of the sale, the insider now owns 10,908,502 shares in the company, valued at approximately $284,711,902.20. This trade represents a 0.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the sale, the chief accounting officer now owns 15,000 shares of the company’s stock, valued at $305,550. The trade was a 90.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 388,916 shares of company stock worth $9,231,268 in the last quarter. 19.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Frazier Life Sciences Management L.P. boosted its stake in shares of NewAmsterdam Pharma by 23.8% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company’s stock valued at $409,052,000 after purchasing an additional 3,061,224 shares during the last quarter. Bain Capital Life Sciences Investors LLC boosted its stake in shares of NewAmsterdam Pharma by 2.3% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 10,719,110 shares of the company’s stock valued at $275,481,000 after purchasing an additional 245,197 shares during the last quarter. RA Capital Management L.P. boosted its stake in shares of NewAmsterdam Pharma by 9.7% in the 4th quarter. RA Capital Management L.P. now owns 8,845,000 shares of the company’s stock valued at $227,316,000 after purchasing an additional 781,000 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its stake in shares of NewAmsterdam Pharma by 378.4% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company’s stock valued at $110,879,000 after purchasing an additional 3,412,590 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of NewAmsterdam Pharma by 291.9% in the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company’s stock valued at $102,763,000 after purchasing an additional 2,978,263 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Trading Down 0.9 %

NASDAQ NAMS opened at $23.37 on Tuesday. The company has a fifty day simple moving average of $21.95 and a 200 day simple moving average of $20.75. The company has a market cap of $2.57 billion, a P/E ratio of -8.99 and a beta of -0.04. NewAmsterdam Pharma has a 1 year low of $15.19 and a 1 year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to analysts’ expectations of $3.30 million. Equities research analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.